Cyclenium signs drug discovery and collaboration agreement with Fundación MEDINA

Emerging pharma company Cyclenium, focused on proprietary macrocyclic chemistry, has signed a drug discovery and collaboration agreement with Fundación MEDINA, a non-profit research organization established through a private-public partnership in Spain.

The collaboration will use Cyclenium’s proprietary QUEST library of macrocyclic molecules and associated hit-to-clinical candidate optimization capabilities in addition to the expertise and experience of Fundación MEDINA in infective disease research. The goal is to discover new anti-infective drug candidates effective against a number of clinically important bacterial and fungal pathogens.

Helmut Thomas, president and chief executive of Cyclenium, said: “We are extremely excited about entering into this unique drug discovery collaboration with the Fundación MEDINA in one of our therapeutic focus areas. The combination of their superb team and world class expertise in anti-infective research with our CMRM Technology and proven development success in the macrocycle arena offers an excellent opportunity for discovering desperately needed novel pharmaceutical agents against high priority, treatment resistant, bacterial and fungal organisms.”